Marker Therapeutics, Inc. reports developments as a clinical-stage immuno-oncology company developing non-genetically modified Multi-Antigen Recognizing T cell therapies for hematologic malignancies and solid tumor indications. Its recurring company updates center on the MAR-T cell platform, MT-601 in lymphoma, MT-401-OTS as an off-the-shelf program, and pancreatic cancer research connected to technology developed at Baylor College of Medicine.
Company news also covers clinical observations from named studies, non-dilutive funding from government and cancer-research programs, scientific publications and medical-meeting presentations, quarterly financial results, conference participation, shareholder voting matters, and board governance changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Marker Therapeutics (Nasdaq: MRKR) reported significant updates regarding its clinical programs and financial results for fiscal year 2022. The company received a $2 million grant from the FDA for the Phase 2 ARTEMIS trial of MT-401 in acute myeloid leukemia (AML) and cleared IND applications for MT-601 targeting metastatic pancreatic cancer and non-Hodgkin lymphoma. The improved T cell manufacturing process for MT-401 has yielded a production time reduction to 9 days and enhanced product efficacy. Financially, Marker reported a net loss of $29.9 million, down from $41.9 million in 2021, and had a cash position of $11.8 million at year-end.
Marker Therapeutics (Nasdaq: MRKR) announced a Common Stock Purchase Agreement with Lincoln Park Capital Fund for up to $25 million. This agreement allows Marker to sell shares at its discretion over a 24-month period, subject to the effectiveness of a registration statement with the SEC. The proceeds will support the Phase 2 ARTEMIS trial of its lead candidate, MT-401, and other clinical programs. CEO Peter Hoang emphasized the importance of this deal for flexible capital access post-restructuring.
Marker Therapeutics, Inc. (Nasdaq: MRKR) announced FDA clearance for its Investigational New Drug (IND) application for MT-601, a T cell product targeting six antigens for patients with advanced pancreatic cancer. The IND approval marks a significant milestone as the company prepares to initiate a Phase 1 clinical trial in 2023. The new manufacturing process for MT-601 allows production in 9 days with a 90% reduction in interventions, improving the final T cell product. The clinical trial follows encouraging results from the Phase 1 TACTOPS study conducted at Baylor College of Medicine.